Elite Pharmaceuticals (STU:ETF) Other Net Income (Loss) : €-0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Other Net Income (Loss)?

Elite Pharmaceuticals's Other Net Income (Loss) for the three months ended in Dec. 2023 was €-0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.00 Mil.

Elite Pharmaceuticals's quarterly Other Net Income (Loss) increased from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€0.00 Mil) but then declined from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil).

Elite Pharmaceuticals's annual Other Net Income (Loss) increased from Mar. 2021 (€-0.00 Mil) to Mar. 2022 (€0.78 Mil) but then declined from Mar. 2022 (€0.78 Mil) to Mar. 2023 (€0.00 Mil).

Elite Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Elite Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Other Net Income (Loss) Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Net Income (Loss)

Get a 7-Day Free Trial

0.60

0.78

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Elite Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Elite Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (STU:ETF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ELTP:USA

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines